Literature DB >> 15894195

Economic burden of osteoporosis, breast cancer, and cardiovascular disease among postmenopausal women in an employed population.

Alicia C Sasser1, Matthew D Rousculp, Howard G Birnbaum, Emily F Oster, Edward Lufkin, David Mallet.   

Abstract

BACKGROUND: Postmenopausal women have a significant risk of developing a number of chronic conditions including osteoporosis (OP), breast cancer (BrCa), and cardiovascular disease (CVD). These diseases can result in significant direct (medical treatment) and indirect (workplace) costs. The objective of this study is to assess these costs among an employed population.
METHODS: Deidentified medical and disability claims data from seven large employers (n = 585,441) were analyzed from 1998 through 2000 for female employees, age 50-64 years. Medical claim ICD-9CM codes were used to identify patients treated for: OP (n = 2,314), BrCa (n = 555), and CVD (n = 1,710). Each disease cohort was compared to a random sample of 50- to 64-year-old female employees (n = 7,575). Descriptive and multivariate techniques were used to characterize direct and indirect costs attributable to each condition.
RESULTS: Average annual direct costs were higher (p < .001) for female employees treated for OP (6,259 dollars), BrCa (13,925 dollars), or CVD (12,055 dollars) when compared with the random sample (2,951 dollars). In addition, average annual indirect costs associated with OP (4,039 dollars), BrCa (8,236 dollars), and CVD (4,990 dollars) were higher (p < .001) than indirect costs for the random sample (2,292 dollars). Even when controlling for each disease-state cohort's demographics and disease-specific comorbidities, patients treated for OP, BrCa, and CVD continued to have significantly greater direct and indirect costs (p < .001) than the random sample.
CONCLUSIONS: Chronic conditions such as OP, BrCa, and CVD, which occur more frequently in women after menopause, impose a significant financial burden. Greater health care utilization and work-loss prevalence among women treated for these conditions contribute to these additional costs.

Entities:  

Mesh:

Year:  2005        PMID: 15894195     DOI: 10.1016/j.whi.2004.11.006

Source DB:  PubMed          Journal:  Womens Health Issues        ISSN: 1049-3867


  29 in total

Review 1.  A review of the cost of cardiovascular disease.

Authors:  Jean-Eric Tarride; Morgan Lim; Marie DesMeules; Wei Luo; Natasha Burke; Daria O'Reilly; James Bowen; Ron Goeree
Journal:  Can J Cardiol       Date:  2009-06       Impact factor: 5.223

2.  The impact of fragility fractures on work and characteristics associated with time to return to work.

Authors:  N K Rotondi; D E Beaton; M Ilieff; C Adhihetty; D Linton; E Bogoch; J Sale; S Hogg-Johnson; S Jaglal; R Jain; J Weldon
Journal:  Osteoporos Int       Date:  2016-08-05       Impact factor: 4.507

Review 3.  Osteoporotic fractures: a systematic review of U.S. healthcare costs and resource utilization.

Authors:  Sangeeta Budhia; Yeshi Mikyas; Michael Tang; Enkhe Badamgarav
Journal:  Pharmacoeconomics       Date:  2012-02-01       Impact factor: 4.981

4.  Work task disability in employed breast and prostate cancer patients.

Authors:  Kathleen Oberst; Cathy J Bradley; Joseph C Gardiner; Maryjean Schenk; Charles W Given
Journal:  J Cancer Surviv       Date:  2010-06-12       Impact factor: 4.442

Review 5.  The societal burden of osteoporosis.

Authors:  David J Becker; Meredith L Kilgore; Michael A Morrisey
Journal:  Curr Rheumatol Rep       Date:  2010-06       Impact factor: 4.592

6.  Medical costs of osteoporosis in the elderly Medicare population.

Authors:  S W Blume; J R Curtis
Journal:  Osteoporos Int       Date:  2010-12-17       Impact factor: 4.507

7.  Direct and indirect costs of non-vertebral fracture patients with osteoporosis in the US.

Authors:  Crystal Pike; Howard G Birnbaum; Matt Schiller; Hari Sharma; Russel Burge; Eric T Edgell
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

8.  Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer.

Authors:  A Blythe Ryerson; Christie R Eheman; Sean F Altekruse; John W Ward; Ahmedin Jemal; Recinda L Sherman; S Jane Henley; Deborah Holtzman; Andrew Lake; Anne-Michelle Noone; Robert N Anderson; Jiemin Ma; Kathleen N Ly; Kathleen A Cronin; Lynne Penberthy; Betsy A Kohler
Journal:  Cancer       Date:  2016-03-09       Impact factor: 6.860

Review 9.  The costs of treating breast cancer in the US: a synthesis of published evidence.

Authors:  Jonathan D Campbell; Scott D Ramsey
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

10.  Simulating and evaluating local interventions to improve cardiovascular health.

Authors:  Jack Homer; Bobby Milstein; Kristina Wile; Justin Trogdon; Philip Huang; Darwin Labarthe; Diane Orenstein
Journal:  Prev Chronic Dis       Date:  2009-12-15       Impact factor: 2.830

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.